GeoVax to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 8, 2023
October 31 2023 - 8:00AM
via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a
clinical-stage biotechnology company developing immunotherapies and
vaccines against cancer and infectious diseases, today announced
that it will report third quarter 2023 financial results on
Wednesday, November 8, 2023, after the close of U.S. markets.
Following the release, management will host a live conference call
and webcast, including Q&A, at 4:30 p.m. ET to provide a
corporate update and discuss financial results.
Dial-in numbers:Domestic:
800-715-9871International:
646-307-1963Conference ID:
7519986
Webcast:A webcast of the live call may be accessed here
and on the Events page of the GeoVax website.A webcast replay of
the call will be available for three months via the same link as
the live webcast approximately two hours after the end of the
call.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company
developing novel therapies and vaccines for solid tumor cancers and
many of the world’s most threatening infectious diseases. The
company’s lead program in oncology is a novel oncolytic solid tumor
gene-directed therapy, Gedeptin®, presently in a multicenter Phase
1/2 clinical trial for advanced head and neck cancers. GeoVax’s
lead infectious disease candidate is GEO-CM04S1, a next-generation
COVID-19 vaccine targeting high-risk immunocompromised patient
populations. Currently in three Phase 2 clinical trials, GEO-CM04S1
is being evaluated as a primary vaccine for immunocompromised
patients such as those suffering from hematologic cancers and other
patient populations for whom the current authorized COVID-19
vaccines are insufficient, and as a booster vaccine in patients
with chronic lymphocytic leukemia (CLL). In addition, GEO-CM04S1 is
in a Phase 2 clinical trial evaluating the vaccine as a more
robust, durable COVID-19 booster among healthy patients who
previously received the mRNA vaccines. GeoVax has a leadership team
who have driven significant value creation across multiple life
science companies over the past several decades. For more
information, visit our website: www.geovax.com.
Company Contact: |
|
Investor Relations Contact: |
|
Media Contact: |
info@geovax.com |
|
paige.kelly@sternir.com |
|
sr@roberts-communications.com |
678-384-7220 |
|
212-698-8699 |
|
202-779-0929 |
|
|
|
|
|
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From May 2024 to Jun 2024
GeoVax Labs (NASDAQ:GOVXW)
Historical Stock Chart
From Jun 2023 to Jun 2024